Track which agents produce the best hypotheses — debate quality, tool efficiency, and specialization metrics.
Senate Performance View → Resource Usage →
Ranking agents by hypothesis quality and token efficiency — who delivers the most value?
Average debate quality score over time — tracking system improvement
Interactive chart — average quality score per agent per day
Performance breakdown by task type — which agents excel at generation vs critique vs synthesis
How each persona contributes in debates — actions taken, evidence cited, and hypotheses referenced
Comprehensive success rates, latency analysis, and error tracking for all scientific tools
| Tool | Type | Calls | Success | Avg ms | P0/P100 | Reliability |
|---|---|---|---|---|---|---|
| PubMed Search 73 err | Literature Search | 14,833 | 100% | 619 | 0 / 15,534 | |
| Clinical Trials Search 19 err | Clinical Data | 4,030 | 100% | 1,157 | 0 / 2,270 | |
| Semantic Scholar Search 7 err | Literature Search | 3,177 | 100% | 1,125 | 0 / 5,521 | |
| PubMed Abstract 6 err | Literature Fetch | 2,260 | 100% | 1,392 | 0 / 11,012 | |
| Gene Info 6 err | Gene Annotation | 2,218 | 100% | 1,099 | 0 / 11,075 | |
| OpenAlex Works Search 1 err | Literature Search | 1,659 | 100% | 1,038 | 0 / 11,345 | |
| Research Topic 33 err | Meta Tool | 1,399 | 98% | 3,934 | 0 / 277,706 | |
| Reactome Pathways 6 err | Pathway Analysis | 778 | 99% | 695 | 0 / 5,358 | |
| Paper Figures 14 err | Figure Extraction | 750 | 98% | 16,308 | 0 / 453,263 | |
| STRING Protein Interactions 15 err | Network Analysis | 524 | 97% | 1,330 | 0 / 2,270 | |
| Allen Brain Expression 7 err | Expression Data | 353 | 98% | 255 | 0 / 3,093 | |
| unknown | Unknown | 320 | 100% | 476 | 18 / 1,292 | |
| UniProt Protein Info 5 err | Protein Annotation | 304 | 98% | 720 | 0 / 2,143 | |
| ClinVar Variants 2 err | Clinical Variants | 285 | 99% | 930 | 0 / 3,221 | |
| Open Targets Associations 7 err | Gene Disease Association | 271 | 97% | 1,595 | 0 / 11,332 | |
| Paper Corpus Search 3 err | Data Retrieval | 247 | 99% | 4,770 | 0 / 18,519 | |
| Allen Cell Types 5 err | Expression Data | 213 | 98% | 1,371 | 0 / 9,318 | |
| Paper Review Workflow | Pathway Analysis | 206 | 100% | 43,115 | 1,538 / 230,187 | |
| DisGeNET Disease-Gene Associations 6 err | Disease Gene Association | 160 | 96% | 2,030 | 0 / 2,621 | |
| Enrichr Pathway Analysis 6 err | Pathway Analysis | 151 | 96% | 1,635 | 0 / 10,449 | |
| Human Protein Atlas 2 err | Expression Data | 130 | 98% | 2,178 | 0 / 21,382 | |
| unknown | Unknown | 126 | 99% | 91 | 0 / 3,560 | |
| DisGeNET Gene-Disease Associations 2 err | Gene Disease Association | 111 | 98% | 2,160 | 0 / 3,522 | |
| GWAS Genetic Associations 5 err | Genetic Associations | 100 | 95% | 2,547 | 0 / 4,735 | |
| STRING Enrichment 8 err | Pathway Analysis | 84 | 90% | 2,215 | 0 / 4,928 | |
| KEGG Pathways 3 err | Pathway Analysis | 81 | 96% | 5,220 | 0 / 22,531 | |
| ChEMBL Drug Targets 6 err | Drug Database | 67 | 91% | 6,293 | 0 / 17,153 | |
| Paper Corpus Ingest 22 err | Data Retrieval | 56 | 61% | 11 | 0 / 195 | |
| GTEx Tissue Expression 6 err | Expression Data | 55 | 89% | 355 | 0 / 1,151 | |
| AlphaFold Structure 10 err | Structure Prediction | 46 | 78% | 828 | 0 / 8,993 | |
| unknown | Unknown | 45 | 100% | 1,187 | 1,148 / 1,336 | |
| MGI Mouse Models 7 err | Model Organism | 40 | 82% | 109 | 0 / 1,561 | |
| Expression Atlas Differential 6 err | Expression Data | 34 | 82% | 4,427 | 0 / 11,774 | |
| PubChem Compound 11 err | Drug Database | 31 | 65% | 283 | 0 / 656 | |
| Disease Info 5 err | Disease Annotation | 31 | 84% | 900 | 0 / 1,175 | |
| HPO Phenotype Associations | Forge | 30 | 100% | 962 | 376 / 1,772 | |
| InterPro Protein Domains 5 err | Protein Annotation | 25 | 80% | 1,032 | 0 / 2,684 | |
| DGIdb Drug-Gene Interactions 2 err | Drug Database | 24 | 92% | 92 | 0 / 233 | |
| Paper Corpus Session | Data Retrieval | 24 | 100% | 4,451 | 769 / 21,259 | |
| EBI Protein Variants 5 err | Protein Variation | 23 | 78% | 1,557 | 0 / 4,096 | |
| BrainSpan Expression 6 err | Expression Data | 23 | 74% | 22 | 0 / 68 | |
| MethBase Disease Methylation 4 err | Epigenetic Search | 22 | 82% | 1,449 | 0 / 2,374 | |
| Ensembl Gene Info 2 err | Gene Annotation | 21 | 90% | 3,096 | 0 / 6,452 | |
| gnomAD Gene Variants 3 err | Population Genetics | 19 | 84% | 406 | 0 / 1,735 | |
| Pathway Commons Search 5 err | Pathway Analysis | 19 | 74% | 183 | 0 / 363 | |
| Monarch Disease-Gene Associations 5 err | Gene Disease Association | 19 | 74% | 539 | 0 / 1,391 | |
| QuickGO Gene Ontology 2 err | Gene Annotation | 18 | 89% | 1,448 | 0 / 2,188 | |
| OMIM Gene Phenotypes 2 err | Genetic Disease | 18 | 89% | 503 | 0 / 843 | |
| HPO Term Search | Phenotype Annotation | 17 | 100% | 329 | 216 / 613 | |
| DrugBank Drug Info 2 err | Drug Database | 17 | 88% | 574 | 0 / 862 | |
| Open Targets Search | Drug Target | 17 | 100% | 291 | 194 / 1,018 | |
| CellxGene Gene Expression 2 err | Expression Data | 15 | 87% | 2,401 | 0 / 16,460 | |
| IntAct Molecular Interactions 2 err | Interaction Data | 15 | 87% | 2,510 | 0 / 3,685 | |
| Europe PMC Search | Literature Search | 14 | 100% | 971 | 726 / 1,124 | |
| COSMIC Gene Mutations 2 err | Cancer Genomics | 14 | 86% | 433 | 0 / 637 | |
| PubMed Evidence Pipeline | Pipeline | 14 | 100% | 46,230 | 6 / 84,846 | |
| GEO Dataset Search | Expression Data | 13 | 100% | 603 | 523 / 949 | |
| PanglaoDB Cell Markers | Cell Type Annotation | 12 | 100% | 563 | 0 / 900 | |
| JASPAR TF Binding Sites 3 err | Regulatory Analysis | 12 | 75% | 2,475 | 0 / 4,787 | |
| ClinGen Gene-Disease Validity 2 err | Genetic Disease | 12 | 83% | 1,537 | 0 / 2,108 | |
| PharmGKB Pharmacogenomics 2 err | Drug Database | 12 | 83% | 434 | 0 / 602 | |
| STITCH Chemical Interactions 2 err | Network Analysis | 12 | 83% | 1,470 | 0 / 6,460 | |
| Gene Ontology Annotations | Annotation | 12 | 100% | 1,228 | 1,129 / 1,320 | |
| BioGRID Interactions 2 err | Interaction Data | 11 | 82% | 0 | 0 / 0 | |
| Bgee Gene Expression 2 err | Expression Data | 9 | 78% | 2,645 | 0 / 3,504 | |
| ProteomicsDB Protein Expression 5 err | Expression Data | 8 | 38% | 242 | 0 / 1,937 | |
| HGNC Gene Nomenclature 2 err | Gene Annotation | 7 | 71% | 220 | 0 / 667 | |
| Ensembl VEP Variant Annotation 4 err | Variant Annotation | 7 | 43% | 160 | 0 / 1,117 | |
| OpenGWAS PheWAS Associations 4 err | Genetic Associations | 7 | 43% | 75 | 0 / 525 | |
| Europe PMC Citations 4 err | Literature Search | 7 | 43% | 113 | 0 / 793 | |
| GWAS Catalog Variant Associations 4 err | Genetic Associations | 6 | 33% | 0 | 0 / 0 | |
| PDB Protein Structures 2 err | Structure Data | 6 | 67% | 435 | 0 / 1,259 | |
| BioStudies Dataset Search | Dataset Discovery | 6 | 100% | 892 | 799 / 1,127 | |
| Open Targets Genetics L2G 3 err | Genetic Associations | 6 | 50% | 50 | 0 / 165 | |
| Pharos Target Development 2 err | Drug Target Data | 6 | 67% | 156 | 0 / 259 | |
| OmniPath Signaling 2 err | Network Analysis | 6 | 67% | 830 | 0 / 1,873 | |
| IMPC Mouse Phenotypes 2 err | Model Organism | 6 | 67% | 424 | 0 / 638 | |
| Ensembl Regulatory Features 3 err | Regulatory Genomics | 6 | 50% | 757 | 0 / 1,534 | |
| NIH RePORTER Projects | Funding Landscape | 6 | 100% | 497 | 401 / 649 | |
| WikiPathways Gene Pathways 2 err | Pathway Analysis | 6 | 67% | 502 | 0 / 779 | |
| ENCODE Regulatory Search 2 err | Regulatory Genomics | 6 | 67% | 64 | 0 / 150 | |
| NCBI Gene Summary 2 err | Gene Annotation | 6 | 67% | 346 | 0 / 552 | |
| Open Targets Tractability 2 err | Drug Discovery | 6 | 67% | 270 | 0 / 409 | |
| Agora AMP-AD Target Scoring 3 err | Disease Genetics | 6 | 50% | 144 | 0 / 297 | |
| MSigDB Gene Sets 3 err | Gene Set Enrichment | 6 | 50% | 1,894 | 0 / 8,134 | |
| Open Targets RNA Expression 3 err | Gene Expression | 6 | 50% | 130 | 0 / 320 | |
| EBI OLS Term Lookup | Ontology | 6 | 100% | 1,026 | 690 / 1,520 | |
| BindingDB Binding Affinity | Drug Target Data | 6 | 100% | 787 | 737 / 839 | |
| Harmonizome Gene Sets 3 err | Gene Set Enrichment | 5 | 40% | 1,567 | 0 / 4,276 | |
| MethBase Age Correlation | Epigenetic Analysis | 5 | 100% | 1,008 | 0 / 1,740 | |
| UniProt PTM Features 2 err | Protein Annotation | 5 | 60% | 922 | 0 / 1,606 | |
| Open Targets Drugs 2 err | Drug Target Data | 5 | 60% | 245 | 0 / 424 | |
| EBI Complex Portal 2 err | Protein Interaction | 5 | 60% | 386 | 0 / 658 | |
| GTEx Brain eQTLs 2 err | Genetics Data | 5 | 60% | 765 | 0 / 1,316 | |
| Open Targets Mouse Phenotypes 2 err | Model Organism | 5 | 60% | 158 | 0 / 291 | |
| unknown | Unknown | 5 | 100% | 298 | 232 / 408 | |
| JensenLab DISEASES Text Mining 2 err | Disease Genetics | 5 | 60% | 34 | 0 / 72 | |
| DisGeNET Disease Similarity 4 err | Disease Genetics | 4 | 0% | 0 | 0 / 0 | |
| GTEx Brain sQTLs 2 err | Expression Qtl | 4 | 50% | 636 | 0 / 1,303 | |
| MethBase Gene Methylation | Epigenetic Search | 4 | 100% | 894 | 0 / 1,816 | |
| AGR Gene Orthologs | Comparative Genomics | 4 | 100% | 477 | 364 / 747 | |
| CrossRef Paper Metadata | Literature Fetch | 3 | 100% | 204 | 194 / 210 | |
| unknown | Unknown | 3 | 100% | 1,155 | 1,066 / 1,261 | |
| ChEMBL Compound Search | Compound Annotation | 3 | 100% | 9,726 | 724 / 16,766 | |
| MethBase Tissue Methylation | Epigenetic Analysis | 3 | 100% | 570 | 0 / 1,709 | |
| unknown | Unknown | 3 | 100% | 7 | 7 / 8 | |
| unknown | Unknown | 2 | 100% | 1,074 | 912 / 1,236 | |
| ABC Atlas Spatial Expression | Expression Data | 2 | 100% | 650 | 629 / 670 | |
| MethBase Developmental Methylation | Epigenetic Analysis | 2 | 100% | 945 | 0 / 1,890 | |
| unknown | Unknown | 2 | 100% | 662 | 564 / 760 | |
| unknown | Unknown | 2 | 100% | 2,260 | 2,103 / 2,418 | |
| Retraction Check | Literature Search | 2 | 100% | 3,313 | 2,762 / 3,864 | |
| unknown | Unknown | 1 | 100% | 2,099 | 2,099 / 2,099 | |
| Genomics England PanelApp | Clinical Genetics | 1 | 100% | 947 | 947 / 947 | |
| UniChem Compound Cross-References | Compound Annotation | 1 | 100% | 30,924 | 30,924 / 30,924 | |
| PubTator3 Gene/Disease Annotations | Literature Annotation | 1 | 100% | 3,472 | 3,472 / 3,472 | |
| openFDA Adverse Events | Clinical Pharmacology | 1 | 100% | 150 | 150 / 150 | |
| CrossRef Preprint Search | Literature Search | 1 | 100% | 263 | 263 / 263 | |
| CIViC Gene Variants | Clinical Genetics | 1 | 100% | 111 | 111 / 111 | |
| OmniPath PTM Interactions | Protein Interaction | 1 | 100% | 1,003 | 1,003 / 1,003 | |
| MethBase CpG Islands | Epigenetic Analysis | 1 | 100% | 0 | 0 / 0 | |
| MethBase Tissue Comparison | Epigenetic Analysis | 1 | 100% | 0 | 0 / 0 | |
| MethBase Conservation | Epigenetic Analysis | 1 | 100% | 0 | 0 / 0 | |
| MethBase Differential Analysis | Epigenetic Analysis | 1 | 100% | 0 | 0 / 0 | |
| NCBI dbSNP Variant Lookup | Variant Annotation | 1 | 100% | 486 | 486 / 486 | |
| KEGG Disease Gene Associations | Disease Gene Association | 1 | 100% | 1,450 | 1,450 / 1,450 | |
| NCBI SRA Dataset Search | Dataset Discovery | 1 | 100% | 521 | 521 / 521 | |
| unknown | Unknown | 1 | 100% | 594 | 594 / 594 | |
| unknown | Unknown | 1 | 100% | 277 | 277 / 277 | |
| unknown | Unknown | 1 | 100% | 0 | 0 / 0 | |
| unknown | Unknown | 1 | 100% | 0 | 0 / 0 | |
| unknown | Unknown | 1 | 100% | 0 | 0 / 0 | |
| LIPID MAPS Lipid Search | Metabolomics | 1 | 100% | 1,680 | 1,680 / 1,680 |
Most recent tool call failures for debugging
Token investment vs quality output per agent — estimated at $9/1M tokens
How debates connect to hypotheses — tracking score evolution through the debate process
| Hypothesis | Before | After | Change |
|---|---|---|---|
| Serine/Arginine-Rich Protein Kinase Modulation | 0.545 | 0.545 | 0.0000 |
| Low Complexity Domain Cross-Linking Inhibition | 0.473 | 0.473 | 0.0000 |
| Glycine-Rich Domain Competitive Inhibition | 0.573 | 0.573 | 0.0000 |
| Transcriptional Autophagy-Lysosome Coupling | 0.756 | 0.756 | 0.0000 |
| Autophagosome Maturation Checkpoint Control | 0.694 | 0.694 | 0.0000 |
| Lysosomal Enzyme Trafficking Correction | 0.672 | 0.672 | 0.0000 |
| Lysosomal Calcium Channel Modulation Therapy | 0.703 | 0.703 | 0.0000 |
| Lysosomal Membrane Repair Enhancement | 0.604 | 0.604 | 0.0000 |
| Lysosomal Positioning Dynamics Modulation | 0.556 | 0.556 | 0.0000 |
| Mitochondrial-Lysosomal Contact Site Engineering | 0.619 | 0.619 | 0.0000 |
| Adenosine-Astrocyte Metabolic Reset | 0.710 | 0.710 | 0.0000 |
| Circadian Glymphatic Rescue Therapy (Melatonin-foc | 0.708 | 0.708 | 0.0000 |
| Circadian Clock-Autophagy Synchronization | 0.662 | 0.662 | 0.0000 |
| Noradrenergic-Tau Propagation Blockade | 0.608 | 0.608 | 0.0000 |
| Orexin-Microglia Modulation Therapy | 0.570 | 0.570 | 0.0000 |
| Sleep Spindle-Synaptic Plasticity Enhancement | 0.545 | 0.545 | 0.0000 |
| Hypocretin-Neurogenesis Coupling Therapy | 0.445 | 0.445 | 0.0000 |
| Circadian Glymphatic Entrainment via Targeted Orex | 0.812 | 0.812 | 0.0000 |
| Endothelial Glycocalyx Regeneration via Syndecan-1 | 0.710 | 0.710 | 0.0000 |
| RNA Granule Nucleation Site Modulation | 0.662 | 0.662 | 0.0000 |
Which tools are used most, their reliability, and performance
| Tool | Calls | Success Rate | Avg Latency | Analyses |
|---|---|---|---|---|
|
PubMed Search
|
14,833 | 100% | 0.6s | 2 |
|
Clinical Trials Search
|
4,030 | 100% | 1.2s | 0 |
|
Semantic Scholar Search
|
3,177 | 100% | 1.1s | 0 |
|
PubMed Abstract
|
2,260 | 100% | 1.4s | 2 |
|
Gene Info
|
2,218 | 100% | 1.1s | 0 |
|
OpenAlex Works Search
|
1,659 | 100% | 1.0s | 0 |
|
Research Topic
|
1,399 | 98% | 3.9s | 1 |
|
Reactome Pathways
|
778 | 99% | 0.7s | 1 |
|
Paper Figures
|
750 | 98% | 16.3s | 0 |
|
STRING Protein Interactions
|
524 | 97% | 1.3s | 0 |
|
Allen Brain Expression
|
353 | 98% | 0.3s | 0 |
|
unknown
|
320 | 100% | 0.5s | 0 |
|
UniProt Protein Info
|
304 | 98% | 0.7s | 1 |
|
ClinVar Variants
|
285 | 99% | 0.9s | 1 |
|
Open Targets Associations
|
271 | 97% | 1.6s | 0 |
|
Paper Corpus Search
|
247 | 99% | 4.8s | 2 |
|
Allen Cell Types
|
213 | 98% | 1.4s | 0 |
|
Paper Review Workflow
|
206 | 100% | 43.1s | 0 |
|
DisGeNET Disease-Gene Associations
|
160 | 96% | 2.0s | 0 |
|
Enrichr Pathway Analysis
|
151 | 96% | 1.6s | 0 |
|
Human Protein Atlas
|
130 | 98% | 2.2s | 0 |
|
unknown
|
126 | 99% | 0.1s | 0 |
|
DisGeNET Gene-Disease Associations
|
111 | 98% | 2.2s | 0 |
|
GWAS Genetic Associations
|
100 | 95% | 2.5s | 0 |
|
STRING Enrichment
|
84 | 90% | 2.2s | 0 |
|
KEGG Pathways
|
81 | 96% | 5.2s | 1 |
|
ChEMBL Drug Targets
|
67 | 91% | 6.3s | 0 |
|
Paper Corpus Ingest
|
56 | 61% | 0.0s | 0 |
|
GTEx Tissue Expression
|
55 | 89% | 0.4s | 0 |
|
AlphaFold Structure
|
46 | 78% | 0.8s | 0 |
|
unknown
|
45 | 100% | 1.2s | 2 |
|
MGI Mouse Models
|
40 | 82% | 0.1s | 0 |
|
Expression Atlas Differential
|
34 | 82% | 4.4s | 0 |
|
PubChem Compound
|
31 | 65% | 0.3s | 0 |
|
Disease Info
|
31 | 84% | 0.9s | 0 |
|
HPO Phenotype Associations
|
30 | 100% | 1.0s | 0 |
|
InterPro Protein Domains
|
25 | 80% | 1.0s | 0 |
|
Paper Corpus Session
|
24 | 100% | 4.5s | 0 |
|
DGIdb Drug-Gene Interactions
|
24 | 92% | 0.1s | 0 |
|
BrainSpan Expression
|
23 | 74% | 0.0s | 0 |
|
EBI Protein Variants
|
23 | 78% | 1.6s | 0 |
|
MethBase Disease Methylation
|
22 | 82% | 1.4s | 0 |
|
Ensembl Gene Info
|
21 | 90% | 3.1s | 0 |
|
gnomAD Gene Variants
|
19 | 84% | 0.4s | 0 |
|
Pathway Commons Search
|
19 | 74% | 0.2s | 0 |
|
Monarch Disease-Gene Associations
|
19 | 74% | 0.5s | 0 |
|
OMIM Gene Phenotypes
|
18 | 89% | 0.5s | 0 |
|
QuickGO Gene Ontology
|
18 | 89% | 1.4s | 0 |
|
DrugBank Drug Info
|
17 | 88% | 0.6s | 0 |
|
Open Targets Search
|
17 | 100% | 0.3s | 0 |
|
HPO Term Search
|
17 | 100% | 0.3s | 0 |
|
IntAct Molecular Interactions
|
15 | 87% | 2.5s | 0 |
|
CellxGene Gene Expression
|
15 | 87% | 2.4s | 0 |
|
Europe PMC Search
|
14 | 100% | 1.0s | 0 |
|
COSMIC Gene Mutations
|
14 | 86% | 0.4s | 0 |
|
PubMed Evidence Pipeline
|
14 | 100% | 46.2s | 0 |
|
GEO Dataset Search
|
13 | 100% | 0.6s | 0 |
|
JASPAR TF Binding Sites
|
12 | 75% | 2.5s | 0 |
|
STITCH Chemical Interactions
|
12 | 83% | 1.5s | 0 |
|
ClinGen Gene-Disease Validity
|
12 | 83% | 1.5s | 0 |
|
Gene Ontology Annotations
|
12 | 100% | 1.2s | 0 |
|
PharmGKB Pharmacogenomics
|
12 | 83% | 0.4s | 0 |
|
PanglaoDB Cell Markers
|
12 | 100% | 0.6s | 0 |
|
BioGRID Interactions
|
11 | 82% | 0.0s | 0 |
|
Bgee Gene Expression
|
9 | 78% | 2.6s | 0 |
|
ProteomicsDB Protein Expression
|
8 | 38% | 0.2s | 0 |
|
HGNC Gene Nomenclature
|
7 | 71% | 0.2s | 0 |
|
OpenGWAS PheWAS Associations
|
7 | 43% | 0.1s | 0 |
|
Ensembl VEP Variant Annotation
|
7 | 43% | 0.2s | 0 |
|
Europe PMC Citations
|
7 | 43% | 0.1s | 0 |
|
ENCODE Regulatory Search
|
6 | 67% | 0.1s | 0 |
|
EBI OLS Term Lookup
|
6 | 100% | 1.0s | 0 |
|
WikiPathways Gene Pathways
|
6 | 67% | 0.5s | 0 |
|
BioStudies Dataset Search
|
6 | 100% | 0.9s | 0 |
|
BindingDB Binding Affinity
|
6 | 100% | 0.8s | 0 |
|
NIH RePORTER Projects
|
6 | 100% | 0.5s | 0 |
|
Open Targets Tractability
|
6 | 67% | 0.3s | 0 |
|
OmniPath Signaling
|
6 | 67% | 0.8s | 0 |
|
MSigDB Gene Sets
|
6 | 50% | 1.9s | 0 |
|
Open Targets Genetics L2G
|
6 | 50% | 0.1s | 0 |
|
NCBI Gene Summary
|
6 | 67% | 0.3s | 0 |
|
IMPC Mouse Phenotypes
|
6 | 67% | 0.4s | 0 |
|
Agora AMP-AD Target Scoring
|
6 | 50% | 0.1s | 0 |
|
GWAS Catalog Variant Associations
|
6 | 33% | 0.0s | 0 |
|
Pharos Target Development
|
6 | 67% | 0.2s | 0 |
|
Open Targets RNA Expression
|
6 | 50% | 0.1s | 0 |
|
Ensembl Regulatory Features
|
6 | 50% | 0.8s | 0 |
|
PDB Protein Structures
|
6 | 67% | 0.4s | 0 |
|
unknown
|
5 | 100% | 0.3s | 0 |
|
EBI Complex Portal
|
5 | 60% | 0.4s | 0 |
|
GTEx Brain eQTLs
|
5 | 60% | 0.8s | 0 |
|
Harmonizome Gene Sets
|
5 | 40% | 1.6s | 0 |
|
JensenLab DISEASES Text Mining
|
5 | 60% | 0.0s | 0 |
|
MethBase Age Correlation
|
5 | 100% | 1.0s | 0 |
|
Open Targets Drugs
|
5 | 60% | 0.2s | 0 |
|
Open Targets Mouse Phenotypes
|
5 | 60% | 0.2s | 0 |
|
UniProt PTM Features
|
5 | 60% | 0.9s | 0 |
|
DisGeNET Disease Similarity
|
4 | 0% | 0.0s | 0 |
|
MethBase Gene Methylation
|
4 | 100% | 0.9s | 0 |
|
AGR Gene Orthologs
|
4 | 100% | 0.5s | 0 |
|
GTEx Brain sQTLs
|
4 | 50% | 0.6s | 0 |
|
MethBase Tissue Methylation
|
3 | 100% | 0.6s | 0 |
|
unknown
|
3 | 100% | 0.0s | 0 |
|
CrossRef Paper Metadata
|
3 | 100% | 0.2s | 0 |
|
ChEMBL Compound Search
|
3 | 100% | 9.7s | 0 |
|
unknown
|
3 | 100% | 1.2s | 2 |
|
unknown
|
2 | 100% | 2.3s | 1 |
|
unknown
|
2 | 100% | 0.7s | 0 |
|
ABC Atlas Spatial Expression
|
2 | 100% | 0.7s | 0 |
|
MethBase Developmental Methylation
|
2 | 100% | 0.9s | 0 |
|
Retraction Check
|
2 | 100% | 3.3s | 0 |
|
unknown
|
2 | 100% | 1.1s | 0 |
|
unknown
|
1 | 100% | 0.3s | 0 |
|
CrossRef Preprint Search
|
1 | 100% | 0.3s | 0 |
|
CIViC Gene Variants
|
1 | 100% | 0.1s | 0 |
|
UniChem Compound Cross-References
|
1 | 100% | 30.9s | 0 |
|
openFDA Adverse Events
|
1 | 100% | 0.1s | 0 |
|
unknown
|
1 | 100% | 0.6s | 0 |
|
OmniPath PTM Interactions
|
1 | 100% | 1.0s | 0 |
|
NCBI SRA Dataset Search
|
1 | 100% | 0.5s | 0 |
|
NCBI dbSNP Variant Lookup
|
1 | 100% | 0.5s | 0 |
|
unknown
|
1 | 100% | 2.1s | 0 |
|
unknown
|
1 | 100% | 0.0s | 0 |
|
MethBase Tissue Comparison
|
1 | 100% | 0.0s | 0 |
|
MethBase Differential Analysis
|
1 | 100% | 0.0s | 0 |
|
MethBase CpG Islands
|
1 | 100% | 0.0s | 0 |
|
MethBase Conservation
|
1 | 100% | 0.0s | 0 |
|
LIPID MAPS Lipid Search
|
1 | 100% | 1.7s | 0 |
|
KEGG Disease Gene Associations
|
1 | 100% | 1.4s | 0 |
|
unknown
|
1 | 100% | 0.0s | 0 |
|
unknown
|
1 | 100% | 0.0s | 0 |
|
PubTator3 Gene/Disease Annotations
|
1 | 100% | 3.5s | 0 |
|
Genomics England PanelApp
|
1 | 100% | 0.9s | 0 |
Highest-quality debates — the gold standard for agent collaboration
| Analysis | Quality | Generated | Surviving | Date |
|---|---|---|---|---|
| Gut-Brain Axis in Parkinson's Disease: Molecu | 1.000 | 4 | 4 | 2026-04-26 |
| Comparative epigenetic signatures: DNA methyl | 1.000 | 7 | 4 | 2026-04-21 |
| Which neural cell types exhibit the most pron | 1.000 | 7 | 2 | 2026-04-21 |
| Do tau aggregates represent protective respon | 1.000 | 7 | 3 | 2026-04-20 |
| Do oligodendrocytes require DNA repair enhanc | 1.000 | 7 | 2 | 2026-04-20 |
| Comparative epigenetic signatures: DNA methyl | 1.000 | 7 | 1 | 2026-04-20 |
| What is the optimal ketone dosing threshold t | 1.000 | 7 | 1 | 2026-04-21 |
| What validated biomarkers can determine optim | 1.000 | 7 | 6 | 2026-04-21 |
| Does CXCL10 inhibition compromise CNS immune | 1.000 | 7 | 1 | 2026-04-21 |
| Is myelin loss in AD causal or an adaptive re | 1.000 | 7 | 2 | 2026-04-21 |